MMDA
MMDA (3-methoxy-4,5-methylenedioxyamphetamine) is a Shulgin-explored amphetamine psychedelic with entactogenic character, a methoxy-substituted analog of MDA. It produces emotional openness with dreamy, sedating psychedelic effects and eyes-closed imagery. Human data are limited to early self-experiment reports.
01 Overview
Documented in PiHKAL, MMDA is described as producing a gentle, introspective, and somewhat sedating state combining empathogenic warmth with mild psychedelia and closed-eye visuals. It is distinct from MDA and MDMA in its dreamier, less stimulating quality.
Modern human pharmacology and safety data are scarce. As a serotonergic phenethylamine it carries neurotoxicity and serotonin-syndrome risk. It is controlled or analog-covered in most jurisdictions.
02 Mechanism
Serotonergic phenethylamine combining monoamine release with 5-HT2A agonism, giving mixed entactogenic and mild psychedelic effects with a sedating profile.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 100–150 mg | Oral | PiHKAL-range estimate |
| Common | 150–250 mg | Oral | Approximate; limited data |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Dreamy entactogenesisIntrospective emotional warmth with a sedating, dreamy quality. | Moderate | Anecdotal | |
| Closed-eye visualsEyes-closed imagery from mild 5-HT2A activity. | Mild-moderate | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeSerotonergic activity can precipitate serotonin toxicity in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Unconfirmed | |
| Nausea and sedationQueasiness and heavy sedation, particularly during onset. | Mild | Common | Anecdotal | |
| Serotonergic neurotoxicityTheoretical axonal neurotoxicity shared with the MDA class. | Severe | Theoretical | Preclinical |